Search | Clinical Trials Finder

Conditions: Kidney Transplant Failure and Rejection
Interventions: Tacrolimus (TAC), Sirolimus, Alemtuzumab, Mycophenolate mofetil (MMF); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hematologic Diseases, Hematologic Malignancy, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
Interventions: CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation, Thiotepa, Cyclophosphamide, Busulfan, Melphalan, Fludarabine; Device · Procedure · Drug
Lead sponsor: Baptist Health South Florida; Other
Eligibility: Up to 74 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: B-Cell Lymphoid Malignancies, Hematologic Malignancy, Non-Hodgkin Lymphoma
Interventions: Hematopoietic Stem Cells from HLA-compatible Related, Hematopoietic Stem Cells from HLA Unrelated; Biological
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years to 74 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hematological Malignancies
Interventions: Haploidentical Allogeneic Transplantation; Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neuroepithelial Tumor, Solid Tumor, Allogeneic Hematopoietic Stem Cell Transplantation
Interventions: Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy, Keratinocyte Growth Factor, Alemtuzumab, Thiotepa, Etoposide, Fludarabine, Melphalan, Tacrolimus, Cyclosporine A, Mycophenolate mofetil; Procedure · Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: Up to 60 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Immunodeficiencies
Interventions: CliniMACs; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 22 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia, Lymphoma, Non-Hodgkin, Hematologic Diseases, Acute GVHD
Interventions: Sirolimus, MMF, BCNU, VP-16, CY, FTBI, BU; Drug
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Crohn Disease
Interventions: CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Prednisone/Methylprenisolone, Palifermin, ATG, Clofarabine, Melphalan, Total Body Irradiation, Rituximab; Device · Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 30 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Stem Cell Leukemia of Unclear Lineage, Graft Versus Host Disease
Interventions: extracorporeal photopheresis; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
Interventions: Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil; Drug
Lead sponsor: University of Utah; Other
Eligibility: Up to 21 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hematologic Malignancies
Interventions: UCB and HPDSC; Procedure
Lead sponsor: Celgene Corporation; Industry
Eligibility: Up to 55 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Graft Versus Host Disease, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions: thiotepa, cyclophosphamide, tacrolimus, methotrexate, sirolimus, total body irradiation; Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 44
States / cities: Phoenix, Arizona • Duarte, California • Oakland, California + 40 more

Conditions: Hematologic Neoplasms
Interventions: Stem cell transplantation, Fludarabine, Cyclophosphamide, Etoposide, Doxorubicin, Vincristine, Prednisone, Methotrexate, Cyclosporine, Apheresis; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions: ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor, T-cell replete HSCT from a related, haploidentical donor; Biological · Drug · Procedure
Lead sponsor: Kiadis Pharma; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 12
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 8 more

Conditions: Leukemia, Lymphoma
Interventions: HSCT, DLI; Procedure · Genetic
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia
Interventions: Venetoclax, Azacitidine, Donor Lymphocyte Infusion; Drug · Biological
Lead sponsor: Antonio M Jimenez Jimenez; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide, Fludarabine Phosphate, Total-Body Irradiation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, X-Ray Imaging; Procedure · Biological · Drug + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HPV 16+ Recurrent or Metastatic Cancer
Interventions: CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16, Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lymphoma
Interventions: Allogeneic stem cell transplantation, Fludarabine, Thiotepa, Methotrexate; Procedure · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease, Beta-thalassemia
Interventions: Total Body Irradiation, Alemtuzumab, Abatacept, Research blood draw; Radiation · Drug · Other
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 4 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: Up to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Undifferentiated Leukemia
Interventions: Cladribine, Cyclophosphamide, Cyclosporine, Cytarabine, Filgrastim, Hematopoietic Cell Transplantation, Mitoxantrone, Mycophenolate Mofetil, Mycophenolate Sodium, Total-Body Irradiation, Idarubicin, Fludarabine, Multigated Acquisition Scan, Echocardiography Test, X-Ray Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection; Drug · Biological · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hematologic Diseases
Interventions: Allogeneic Stem Cell Transplant, CliniMACS Prodigy System, T-allo10 cells addback; Biological · Device · Drug
Lead sponsor: Porteus, Matthew, MD; Other
Eligibility: 1 Month to 45 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
Interventions: atorvastatin, Tacrolimus, methotrexate; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies

Reduced Intensity Haploidentical Transplant for Hematological Malignancies

A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation for T and B Cell Depletion

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders

Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood

Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma

Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation